Drugs / gp100:ES209-217 (210M)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001705 | Jul 1998 → Jun 2001 | melanoma, metastatic malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100:ES209-217 (210M) | “This peptide called gp100:ES209-217 (210M) will be administered either alone or in combination with high or low dose IL-2.” NCT00001705 ↗ |
| Modality | Peptide | “modified peptide from the gp100 molecule” NCT00001705 ↗ |